Lupin Launches Generic Edarbi in US, Secures 180-Day Exclusivity
Written By : MD Bureau
Published On 2026-06-18 18:15 GMT | Update On 2026-06-18 18:15 GMT
Advertisement
Mumbai: Global pharma major Lupin Limited (Lupin) has announced the launch of Azilsartan Medoxomil Tablets, 40mg and 80mg in the United States following the approval from the U.S. FDA for its Abbreviated New Drug Application.
The product is bioequivalent to Edarbi of Azurity Pharmaceuticals, Inc. and indicated for the treatment of hypertension in adults to lower blood pressure. Lupin is the exclusive first-to-file for this product and is eligible for 180-day generic drug exclusivity.
Azilsartan Medoxomil Tablets (RLD Edarbi) had estimated annual sales of USD 53.5 million in the U.S. (IQVIA MAT APRIL 2026)
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.